[The national health authority and the responsibility for cost-effective drug utilization].
Meland
E
E
Wapler
P
P
D003362:Cost-Benefit Analysis; D004345:Drug Industry / Q000191:economics; D004363:Drug Utilization / Q000191:economics*; D005194:Family Practice / Q000191:economics; D006801:Humans; D009664:Norway; D013222:State Medicine / Q000191:economics*